Source: Lab Bulletin

Revvity : Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

Revvity, Inc.has announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introduction of an automated next-generation sequencing (NGS) workflow for newborn sequencing research and strengthens Element's momentum towards regulatory approval of the benchtop AVITI sequencing system...

Read full article »
Annual Revenue
$1.0-5.0B
Employees
10-50K
Prahlad Singh's photo - President & CEO of Revvity

President & CEO

Prahlad Singh

CEO Approval Rating

- -/100

Read more